Lantheus joins Bracco for promotion of CardioGen-82
Lantheus Medical Imaging has entered an agreement to co-promote Bracco’s CardioGen-82, a myocardial perfusion PET imaging agent.

CardioGen-82 (Rubidium Rb 82 generator) is an FDA-approved PET perfusion agent, which qualifies for reimbursements for the evaluation of coronary artery disease, according to the North Billerica, Mass.-based Lantheus and the Princeton, N.J.-based Bracco.

Don Kiepert, president and CEO of Lantheus, said the co-promotion agreement is a fit for the company and demonstrates its commitment to the field of diagnostic imaging through its distribution network, customer service and sales and medical affairs field organization.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup